Copanlisib Pharmacodynamic Study

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

August 12, 2014

Primary Completion Date

October 4, 2016

Study Completion Date

March 16, 2017

Conditions
Non Hodgkin Lymphoma
Interventions
DRUG

Copanlisib (BAY80-6946)

0.8 mg/kg body weight and 0.4 mg/kg (not to exceed 65 mg) for the non-diabetic patients;45 mg and 60 mg for the diabetic patients; Intravenous (IV) infusion over 1 hour. Dosing of copanlisib will be on Days 1, 8, and 15 of each 28 day treatment cycle.

Trial Locations (9)

1000

Bruxelles - Brussel

1200

Bruxelles - Brussel

9000

Ghent

14076

Caen

59037

Lille

69495

Pierre-Bénite

06102

Nice

SM2 5PT

Sutton

W1G 6AD

London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY

NCT02155582 - Copanlisib Pharmacodynamic Study | Biotech Hunter | Biotech Hunter